Please login to the form below

Not currently logged in
Email:
Password:

fulranumab

This page shows the latest fulranumab news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Teva close gap on rivals with NGF pain drug

Regeneron and Teva close gap on rivals with NGF pain drug

Amgen was also developing an NGF inhibitor called fulranumab – formerly partnered with Johnson &Johnson and Takeda – but the collaborators handed back rights in 2016 and the drug  no longer features in

Latest news

  • FDA fast-tracks Pfizer and Lilly's tanezumab FDA fast-tracks Pfizer and Lilly's tanezumab

    One competitor - Amgen - has been developing its own candidate called fulranumab, but former partners Johnson &Johnson and Takeda handed back rights to the project last year.

  • FDA halts study of Teva and Regeneron's pain drug fasinumab FDA halts study of Teva and Regeneron's pain drug fasinumab

    Earlier this year, prospects for one of the most advanced candidates - Amgen's fulranumab - took a dive after licensees Johnson &Johnson and Takeda both decided to hand back rights, although they

  • Takeda hands back rights to two Amgen drugs Takeda hands back rights to two Amgen drugs

    However, Takeda has decided it is no longer interested in developing pain candidate fulranumab (AMG403) and trebananib (AMG386), which is being tested in cancer. ... J&J insisted that its decision to drop out of the fulranumab partnership stemmed from

  • Regeneron says anti-NGF fasinumab works in pain Regeneron says anti-NGF fasinumab works in pain

    A few weeks ago Johnson &Johnson (J&J) returned rights to its fulranumab candidate to originator company Amgen, despite the drug already being in multiple phase III trials.

  • J&J drops NGF blocker fulranumab J&J drops NGF blocker fulranumab

    J&J drops NGF blocker fulranumab. Says decision to return rights to Amgen based on “ strategic portfolio prioritisation”. ... Johnson &Johnson has returned the rights to fulranumab to Amgen, raising another question mark over the role of nerve growth

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics